Alkem Laboratories has signed a licensing agreement with Sonnet BioTherapeutics to develop and commercialize the drug SON-080 for diabetic peripheral neuropathy in India, which has shown promising results in early trials.
AI Assistant
Alkem Laboratories Ltd
2024
Announcement
Find Answers
Ask about any part of the document to get insights, explanations, or key details.